424 related articles for article (PubMed ID: 12485462)
21. COX-2 inhibitors in oncology.
Haller DG
Semin Oncol; 2003 Aug; 30(4 Suppl 12):2-8. PubMed ID: 14508721
[No Abstract] [Full Text] [Related]
22. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.
Davis TW; O'Neal JM; Pagel MD; Zweifel BS; Mehta PP; Heuvelman DM; Masferrer JL
Cancer Res; 2004 Jan; 64(1):279-85. PubMed ID: 14729635
[TBL] [Abstract][Full Text] [Related]
23. The role of COX-2 inhibition in breast cancer treatment and prevention.
Arun B; Goss P
Semin Oncol; 2004 Apr; 31(2 Suppl 7):22-9. PubMed ID: 15179621
[TBL] [Abstract][Full Text] [Related]
24. Cyclooxygenase-2 expression and effect of celecoxib in flurothyl-induced neonatal seizure.
Kim DK; Jang TJ
Int J Exp Pathol; 2006 Feb; 87(1):73-8. PubMed ID: 16436115
[TBL] [Abstract][Full Text] [Related]
25. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Howe LR; Subbaramaiah K; Patel J; Masferrer JL; Deora A; Hudis C; Thaler HT; Muller WJ; Du B; Brown AM; Dannenberg AJ
Cancer Res; 2002 Oct; 62(19):5405-7. PubMed ID: 12359744
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological analysis of cyclooxygenase-1 in inflammation.
Smith CJ; Zhang Y; Koboldt CM; Muhammad J; Zweifel BS; Shaffer A; Talley JJ; Masferrer JL; Seibert K; Isakson PC
Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13313-8. PubMed ID: 9789085
[TBL] [Abstract][Full Text] [Related]
27. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
28. Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.
Fong LY; Zhang L; Jiang Y; Farber JL
J Natl Cancer Inst; 2005 Jan; 97(1):40-50. PubMed ID: 15632379
[TBL] [Abstract][Full Text] [Related]
29. Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application.
Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
J Neurosurg; 2005 Sep; 103(3):508-17. PubMed ID: 16235684
[TBL] [Abstract][Full Text] [Related]
30. Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide.
Denda A; Kitayama W; Murata A; Kishida H; Sasaki Y; Kusuoka O; Tsujiuchi T; Tsutsumi M; Nakae D; Takagi H; Konishi Y
Carcinogenesis; 2002 Feb; 23(2):245-56. PubMed ID: 11872629
[TBL] [Abstract][Full Text] [Related]
31. Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention.
Yu J; Tang BD; Leung WK; To KF; Bai AH; Zeng ZR; Ma PK; Go MY; Hu PJ; Sung JJ
World J Gastroenterol; 2005 Jan; 11(1):41-5. PubMed ID: 15609394
[TBL] [Abstract][Full Text] [Related]
32. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition.
Pentland AP; Schoggins JW; Scott GA; Khan KN; Han R
Carcinogenesis; 1999 Oct; 20(10):1939-44. PubMed ID: 10506108
[TBL] [Abstract][Full Text] [Related]
33. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
Kato S; Ogawa Y; Kanatsu K; Okayama M; Watanabe T; Arakawa T; Takeuchi K
J Pharmacol Exp Ther; 2002 Nov; 303(2):503-9. PubMed ID: 12388629
[TBL] [Abstract][Full Text] [Related]
34. COX-2 inhibitors: cancer trials test new uses for pain drug.
Michalowski J
J Natl Cancer Inst; 2002 Feb; 94(4):248-9. PubMed ID: 11854385
[No Abstract] [Full Text] [Related]
35. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
[TBL] [Abstract][Full Text] [Related]
36. Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation.
Hsueh SF; Lu CY; Chao CS; Tan PH; Huang YW; Hsieh SW; Hsiao HT; Chung NC; Lin SH; Huang PL; Lyu PC; Yang LC
Brain Res Mol Brain Res; 2004 Jun; 125(1-2):113-9. PubMed ID: 15193428
[TBL] [Abstract][Full Text] [Related]
37. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment.
Swamy MV; Cooma I; Patlolla JM; Simi B; Reddy BS; Rao CV
Mol Cancer Ther; 2004 Feb; 3(2):215-21. PubMed ID: 14985462
[TBL] [Abstract][Full Text] [Related]
38. Inducible nitric oxide synthase expression of tumor and stromal cells is associated with the progression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Jang TJ; Kim DK
Cancer Lett; 2002 Aug; 182(2):121-6. PubMed ID: 12048156
[TBL] [Abstract][Full Text] [Related]
39. Selective COX-2 inhibitors as chemopreventive and therapeutic agents.
Grossman HB
Drugs Today (Barc); 2003 Mar; 39(3):203-12. PubMed ID: 12730704
[TBL] [Abstract][Full Text] [Related]
40. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats.
Nakatsugi S; Ohta T; Kawamori T; Mutoh M; Tanigawa T; Watanabe K; Sugie S; Sugimura T; Wakabayashi K
Jpn J Cancer Res; 2000 Sep; 91(9):886-92. PubMed ID: 11011115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
